Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate

Pediatric Transplantation

Volumn 10, Issue 7, 2006, Pages 830-834

  Termuhlen, Amanda M ^a,c   Grovas, Alfred ^b   Klopfenstein, Kathryn ^a,c   Rosselet, Robin ^c   Gross, Thomas G ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Hematopoietic stem cell transplant; Neuroblastoma; Renal complications; Wilms' tumor

Indexed keywords

ANTIHYPERTENSIVE AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOPAMINE; DOXORUBICIN; ERYTHROPOIETIN; IFOSFAMIDE; MELPHALAN; MONOCLONAL ANTIBODY; RETINOIC ACID; THIOTEPA; VINCRISTINE;

ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CASE REPORT; CATHETER INFECTION; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG SAFETY; FATALITY; FEMALE; GALLBLADDER DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; MUCOSA INFLAMMATION; NEPHRECTOMY; NEPHROBLASTOMA; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PREOPERATIVE CARE; PRESCHOOL CHILD; UREA NITROGEN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; KIDNEY NEOPLASMS; MELPHALAN; NEUROBLASTOMA; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WILMS TUMOR;

EID: 33749566329     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00589.x     Document Type: Article

References (20)

1. CAMPBELL AD, COHN SL, REYNOLDS M, et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: The experience at Children's Memorial Hospital. J Clin Oncol 2004: 22: 2885-2890.
2. PEIN F, MICHON J, VALTEAU-COUANET D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: A French Society of Pediatric Oncology study. J Clin Oncol 1998: 16: 3295-3301.
3. KREMENS B, GRUHN B, KLINGEBIEL T, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 2002: 30: 893-898.
4. MATTHAY KK, VILLABLANCA JG, SEEGER RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999: 341: 1165-1173.
5. BADROS A, BARLOGIE B, SIEGEL E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001: 114: 822-829.
6. CARLSON K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: Impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005: 35: 985-990.
7. HAMAKI T, KATORI H, KAMI M, et al. Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. Bone Marrow Transplant 2002: 30: 195-198.
8. SCHWARTZ GJ, BRION LP, SPITZER A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987: 34: 571-590.
9. TRICOT G, ALBERTS DS, JOHNSON C, et al. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 1996: 2: 947-952.
10. NIETO Y, VAUGHAN WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004: 33: 259-269.
11. JACOBSON PA, GREEN K, BIRNBAUM A, REMMEL RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002: 49: 461-467.
12. KLETZEL M, PIRICH L, HAUT P, COHN RA. Comparison of Tc-99 measurement of glomerular filtration rate vs. calculated creatinine clearance to assess renal function pretransplant in pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Transplant 2005: 9: 584-588.
13. FRISK P, BRATTEBY LE, CARLSON K, LONNERHOLM G. Renal function after autologous bone marrow transplantation in children: A long-term prospective study. Bone Marrow Transplant 2002: 29: 129-136.
14. HAYSOM L, ZIEGLER DS, COHN RJ, et al. Retinoic acid may increase the risk of bone marrow transplant nephropathy. Pediatr Nephrol 2005: 20: 534-538.
15. TURMAN MA, HAMMOND S, GROVAS A, RAUCK AM. Possible association of retinoic acid with bone marrow transplant nephropathy. Pediatr Nephrol 1999: 13: 755-758.
16. MOULDER JE, FISH BL, REGNER KR, et al. Retinoic acid exacerbates experimental radiation nephropathy. Radiat Res 2002: 157: 199-203.
17. BELLOMO R, CHAPMAN M, FINFER S, et al. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000: 356: 2139-2143.
18. FRIEDRICH JO, ADHIKARI N, HERRIDGE MS, BEYENE J. Metaanalysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005: 142: 510-524.
19. HOLMES CL, WALLEY KR. Bad medicine: Low-dose dopamine in the ICU. Chest 2003: 123: 1266-1275.
20. SIROHI B, POWLES R, KULKARNI S, et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001: 85: 325-332.